The July 2026 PCAC meeting: seven peptides and how the 503A bulks list actually works
On 23 and 24 July 2026, FDA’s Pharmacy Compounding Advisory Committee met at the agency’s White Oak campus to consider seven peptide bulk drug substances for possible inclusion on the Section 503A Bulk Drug Substances List. The meeting was announced in the Federal Register on 16 April 2026, ran under docket FDA-2025-N-6895, and was accompanied by an unusually substantial set of published briefing documents — one per substance, several running to multiple megabytes of review.
Because the substances involved are among the most frequently discussed in research peptide contexts, the meeting has been widely referenced since. It has also been widely mischaracterised. This post sets out what was actually on the agenda, what the 503A bulks list mechanism does, and why the outcome has limited bearing on research-use-only material.
What was on the agenda
The committee reviewed each substance against one or more specific proposed uses. FDA’s published agenda identified those uses explicitly, which is worth reproducing precisely, because the pairing of substance to evaluated use is a feature of the review rather than an editorial choice.
On 23 July the committee considered four substances, each in free base and acetate forms:
| Substance | Use evaluated |
|---|---|
| BPC-157 | Ulcerative colitis |
| KPV | Wound healing and inflammatory conditions |
| TB-500 | Wound healing |
| MOTS-c | Obesity and osteoporosis |
On 24 July it considered three more:
| Substance | Use evaluated |
|---|---|
| Emideltide (delta sleep-inducing peptide, DSIP) | Opioid withdrawal, chronic insomnia, narcolepsy |
| Semax | Cerebral ischaemia, migraine, trigeminal neuralgia |
| Epitalon | Insomnia |
An important reading note: the “use evaluated” column records the indication FDA’s review team assessed, generally reflecting what the nominator proposed. It is not a statement that the substance works for that indication, and a substance appearing in this table should not be taken as evidence of efficacy for anything. The review exists precisely to interrogate whether the supporting evidence is adequate.
For nominated substances, nominators were invited to present in support of their nominations, and a public docket accepted written comment until 22 July.
What the 503A bulks list is
Section 503A of the Federal Food, Drug, and Cosmetic Act sets the conditions under which a licensed pharmacist or physician may compound a drug product for an identified individual patient without that product going through new drug approval. One of those conditions concerns the starting material. A bulk drug substance may be used in 503A compounding only if it satisfies one of three tests: it is the subject of an applicable USP or NF monograph, it is a component of an FDA-approved drug, or it appears on a list of bulk substances FDA has developed for this purpose.
That third route is the 503A bulks list, and it is the subject of the PCAC process. The mechanism runs: nomination by an interested party, FDA review of the available evidence, referral to PCAC for an advisory recommendation, and — if FDA elects to proceed — notice-and-comment rulemaking to place the substance on the list.
Two structural features of this process are routinely lost in summary.
First, PCAC recommendations are advisory and non-binding. The committee votes; FDA decides. The agency generally follows advisory committee recommendations but is under no legal obligation to do so, and the formal legal effect arrives only with a final rule.
Second, while nominations are pending, FDA has operated an interim categorisation. Category 1 covers substances that may be eligible and against which the agency does not intend to take action pending rulemaking. Category 2 covers substances raising significant safety concerns. Category 3 covers substances for which the nomination lacked sufficient supporting information. These categories describe enforcement posture during an interim period; none of them is an approval.
The April 2026 Category 2 removals
In April 2026 FDA announced the removal of twelve peptide bulk substances from Category 2. This was reported quickly and interpreted badly, so the mechanism is worth stating plainly: the removals followed withdrawal of the nominations by the nominators. A substance with no live nomination does not need an interim category, because there is no pending consideration to categorise.
The inference that does not follow is that removal from Category 2 constitutes clearance. It does not move a substance to Category 1, and it does not make it eligible for 503A compounding. A substance can be absent from Category 2 and remain entirely ineligible — indeed, withdrawal of a nomination removes the only pathway by which it might have become eligible. Removal from a list of concerns is not addition to a list of permissions.
Several substances not scheduled for the July meeting — including cathelicidin LL-37, dihexa acetate, GHK-Cu for injectable routes, pegylated mechano growth factor, and melanotan II — have been indicated for separate PCAC consultation on a later timeline.
Why this sits alongside, not on top of, research-use material
The 503A framework governs compounding of preparations for administration to identified human patients by licensed practitioners. Research-use-only material occupies a different position entirely: it is not compounded, not dispensed against a prescription, and not lawfully directed toward human administration at all. A PCAC recommendation about whether a pharmacy may compound BPC-157 for ulcerative colitis does not create, expand or restrict any pathway for research-grade material.
What the process does supply, and what makes it genuinely worth following, is evidence review. FDA’s briefing documents for these substances are among the most thorough publicly available syntheses of the physicochemical characterisation, animal studies, and human data for compounds that have otherwise been discussed largely outside the peer-reviewed literature. For anyone working with these peptides analytically, the characterisation sections are a substantive reference regardless of what the committee recommended.
It is also worth flagging a documentation hazard that has grown alongside this regulatory activity. A considerable volume of secondary commentary now circulates describing FDA actions — including a purported final guidance specifically governing research-grade peptides — that cannot be traced to any FDA-published document. Regulatory claims of this kind are checkable: FDA guidances appear in the agency’s guidance database, meetings and dockets appear in the Federal Register, and advisory committee materials appear on the committee’s own page. A regulatory assertion that cannot be resolved to one of those sources should be treated as unverified, whatever its apparent confidence and however often it is repeated.
Selected sources
- July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee — FDA, agenda, evaluated uses, and briefing documents.
- Federal Register notice of the meeting and establishment of docket FDA-2025-N-6895, 16 April 2026.
- 2026 Meeting Materials, Pharmacy Compounding Advisory Committee — FDA.
- FDA announces removal of 12 peptides from Category 2 and schedules PCAC meetings — Orrick, April 2026.
At the time of writing, this post describes the agenda, the published review materials and the statutory process. It does not report committee vote outcomes, which were not confirmable from primary FDA sources when this was prepared, and any final regulatory effect would in any case arrive through subsequent rulemaking rather than through the vote itself.
Research Use Only — Disclaimer
All compounds discussed in this article are described for laboratory and research purposes only. They are intended exclusively for in vitro experimentation and use in animal studies under appropriate institutional oversight. They are not drugs, dietary supplements, cosmetics, or food additives. They are not for human consumption and not for any therapeutic, diagnostic, preventive, or palliative purpose.
Nothing in this article constitutes medical advice or legal advice. No statement should be interpreted as a recommendation that any peptide compound is safe, effective, or appropriate for any use in humans, or that any specific regulatory action is appropriate or inappropriate. Indications listed above reflect what FDA reviewed and imply nothing about efficacy.